The FDA says retatrutide falls one alpha amino acid short. A biologic label would mean 12 years of exclusivity instead of 5, a later Medicare price clock and no compounding.
Recap by typeshit. Full story at The American Journal of Managed Care.
A lawyer named Jeff walks through how his side argues Ozempic, Wegovy and other semaglutide drugs may be linked to NAION, a serious form of sudden vision loss.
Stavros Nicolaou of the Pharmaceutical Task Group wants police to act. SAHPRA says it has seized products and opened criminal cases.
The physician group is pushing back on an FDA plan that would open interim access to unapproved peptides, and wants the White House to block it.
Investigators turned up a warehouse of empty pens and a farm building used as a drug factory, as counterfeit weight loss injection sellers grow more organized.
7:05
A doctor-led channel runs through ten points to consider before beginning GLP-1 treatment.
Neither has a controlled human trial for sports injuries. An FDA advisory panel voted 8 to 6 in July 2026 to back compounding BPC-157, but the FDA has not decided.
Loading…